FinnProstate Group

Add links
From Wikipedia, the free encyclopedia

The FinnProstate Group (FP), or FinnProstate Study Group, is a group of scientific researchers in Finland who have conducted a series of clinical trials of treatments for prostate cancer.[1] The first publication by the group was in 1985[2] and the latest publication was in 2019.[3]

Clinical trials[edit]

The studies conducted by the FinnProstate group include the following:[1]

Related trials[edit]

A related study, by the Finnish Zoladex Multicentre Study Group, assessed polyestradiol phosphate versus goserelin for advanced prostate cancer.[1][19] A British group also assessed polyestradiol phosphate 160 mg/month versus orchiectomy for advanced prostate cancer.[1][20] The SPCG-5 trial assessed polyestradiol phosphate 240 mg/month versus combined androgen blockade (triptorelin or orchiectomy plus flutamide) for advanced prostate cancer.[1][21][22][23]

See also[edit]

References[edit]

  1. ^ a b c d e Emmans Dean M, Norman G, Hodges Z, Ritchie G, Light K, Eastwood A, Langley R, Sydes M, Parmar M, Abel P (2006), Parenteral Oestrogens for Prostate Cancer: A Systematic Review of Clinical Effectiveness and Dose Response (CRD Report 33) (PDF), York: Centre for Reviews and Dissemination/University of York/York Publishing Services, ISBN 1900640376, archived from the original (PDF) on 2021-09-08
  2. ^ a b Haapiainen R, Rannikko S, Ruutu M, Ala-Opas M, Aro J, Ervasti J, Hansson E, Hurme K, Juusela H, Mäkinen J (1985). "Early results of the Finnish Multicentre Study of Prostatic Cancer (Finnprostate)". Ann Chir Gynaecol. 74 (6): 277–83. PMID 4096480.
  3. ^ a b Hackman G, Taari K, Tammela TL, Matikainen M, Kouri M, Joensuu T, Luukkaala T, Salonen A, Isotalo T, Pétas A, Hendolin N, Boström PJ, Aaltomaa S, Lehtoranta K, Hellström P, Riikonen J, Korpela M, Minn H, Kellokumpu-Lehtinen PL, Pukkala E, Hemminki A (November 2019). "Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension". Eur Urol. 76 (5): 586–595. doi:10.1016/j.eururo.2019.07.001. hdl:10138/306830. PMID 31375279. S2CID 199389424.
  4. ^ Haapiainen R, Rannikko S, Alfthan O (April 1986). "Comparison of primary orchiectomy and estrogen therapy in advanced prostatic cancer - a 2 years follow-up". Journal of Urology. 135 (4): A339.
  5. ^ Haapiainen R, Rannikko S, Alfthan O (October 1986). "Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study". Br J Urol. 58 (5): 528–33. doi:10.1111/j.1464-410x.1986.tb05461.x. PMID 3779355.
  6. ^ Aro JL, Haapiainen RK, Rannikko SA, Alfthan OS (May 1989). "High dose polyoestradiol phosphate with and without acetosalicylic acid versus orchiectomy in the treatment of prostatic cancer. Finnprostate Group". Br J Urol. 63 (5): 512–4. doi:10.1111/j.1464-410x.1989.tb05946.x. PMID 2659136.
  7. ^ Haapiainen R, Rannikko S, Alfthan O (July 1990). "Comparison of primary orchiectomy and polyoestradiol phosphate in the treatment of advanced prostatic cancer. Finnprostate Group". Br J Urol. 66 (1): 94–7. doi:10.1111/j.1464-410x.1990.tb14872.x. PMID 2132303.
  8. ^ Aro J, Ruutu M, Juusela H, Hansson E, Permi J (1993). "Polyestradiol phosphate (160 mg/month) or LHRH analog (buserelin depot) in the treatment of locally advanced or metastasized prostatic cancer. The Finnprostate Group". Ann Chir Gynaecol Suppl. 206: 5–8. PMID 8291869.
  9. ^ Mikkola AK, Ruutu ML, Aro JL, Rannikko SA, Salo JO (July 1998). "Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group". Br J Urol. 82 (1): 63–8. doi:10.1046/j.1464-410x.1998.00688.x. PMID 9698663.
  10. ^ Mikkola A, Aro J, Rannikko S, Oksanen H, Ruutu M (2005). "Cardiovascular complications in patients with advanced prostatic cancer treated by means of orchiectomy or polyestradiol phosphate". Scand J Urol Nephrol. 39 (4): 294–300. doi:10.1080/00365590510031228. PMID 16261661. S2CID 24752258.
  11. ^ Mikkola A, Aro J, Rannikko S, Ruutu M (March 2007). "Ten-year survival and cardiovascular mortality in patients with advanced prostate cancer primarily treated by intramuscular polyestradiol phosphate or orchiectomy". Prostate. 67 (4): 447–55. doi:10.1002/pros.20547. PMID 17219379. S2CID 20549248.
  12. ^ Mikkola AK, Aro JL, Rannikko AS, Ruutu ML (May 2008). "A high pretreatment plasma oestradiol level is associated with a low risk of acute myocardial infarction in parenteral oestrogen therapy for locally advanced prostate cancer". BJU Int. 101 (9): 1090–5. doi:10.1111/j.1464-410X.2007.07361.x. PMID 18070186. S2CID 2843818.
  13. ^ Mikkola A, Aro J, Rannikko S, Ruutu M (2009). "Prognostic grouping of metastatic prostate cancer using conventional pretreatment prognostic factors". Scand J Urol Nephrol. 43 (4): 265–70. doi:10.1080/00365590902836500. PMID 19382005. S2CID 24321902.
  14. ^ Mikkola AK, Aro JL, Rannikko SA, Salo JO (May 1999). "Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer. FINNPROSTATE Group". Prostate. 39 (3): 175–81. doi:10.1002/(sici)1097-0045(19990515)39:3<175::aid-pros5>3.0.co;2-e. PMID 10334106. S2CID 38212069.
  15. ^ Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL (June 2012). "The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer". J Urol. 187 (6): 2074–81. doi:10.1016/j.juro.2012.01.122. PMID 22498230.
  16. ^ Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL (January 2013). "Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects". Eur Urol. 63 (1): 111–20. doi:10.1016/j.eururo.2012.07.040. PMID 22857983.
  17. ^ Salonen AJ, Taari K, Ala-Opas M, Sankila A, Viitanen J, Lundstedt S, Tammela TL (December 2014). "Comparison of intermittent and continuous androgen deprivation and quality of life between patients with locally advanced and patients with metastatic prostate cancer: a post hoc analysis of the randomized FinnProstate Study VII". Scand J Urol. 48 (6): 513–22. doi:10.3109/21681805.2014.901410. PMID 24679247. S2CID 24864704.
  18. ^ Aro J (1991). "Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population". Prostate. 18 (2): 131–7. doi:10.1002/pros.2990180205. PMID 2006119. S2CID 27915767.
  19. ^ Lukkarinen O, Kontturi M (June 1994). "Comparison of a long-acting LHRH agonist and polyoestradiol phosphate in the treatment of advanced prostatic carcinoma. An open prospective, randomized multicentre study". Scand J Urol Nephrol. 28 (2): 171–8. doi:10.3109/00365599409180495. PMID 7939468.
  20. ^ Bishop MC, Lemberger RJ, Selby C, Lawrence WT (September 1989). "Oestrogen dosage in prostatic cancer: the threshold effect?". Br J Urol. 64 (3): 290–6. doi:10.1111/j.1464-410x.1989.tb06016.x. PMID 2679960.
  21. ^ Hedlund PO, Henriksson P (March 2000). "Parenteral estrogen versus total androgen ablation in the treatment of advanced prostate carcinoma: effects on overall survival and cardiovascular mortality. The Scandinavian Prostatic Cancer Group (SPCG)-5 Trial Study". Urology. 55 (3): 328–33. doi:10.1016/s0090-4295(99)00580-4. PMID 10699602.
  22. ^ Hedlund PO, Ala-Opas M, Brekkan E, Damber JE, Damber L, Hagerman I, Haukaas S, Henriksson P, Iversen P, Pousette A, Rasmussen F, Salo J, Vaage S, Varenhorst E (2002). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer -- Scandinavian Prostatic Cancer Group (SPCG) Study No. 5". Scand J Urol Nephrol. 36 (6): 405–13. doi:10.1080/003655902762467549. PMID 12623503. S2CID 2799580.
  23. ^ Hedlund PO, Damber JE, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Viitanen J (2008). "Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5". Scand J Urol Nephrol. 42 (3): 220–9. doi:10.1080/00365590801943274. PMID 18432528. S2CID 38638336.
Retrieved from "https://en.wikipedia.org/w/index.php?title=FinnProstate_Group&oldid=1185517594"